Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 0.52 a new company low.

Within Major Pharmaceutical Preparations industry 377 other companies have achieved higher Quick Ratio than Apollomics Inc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 2521.

Explain Quick Ratio?
How much Cash & cash equivalents APLM�s has?
What are APLM�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

APLM Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	-	-	-53.33 %	-53.33 %	-
Y / Y Cash & cash equivalent Change	-66.46 %	-87.37 %	-89.78 %	-89.78 %	-61.39 %
Quick Ratio MRQ	0.52	0.52	0.52	0.52	-
APLM's Total Ranking	# 2521	#	#	#	#
Seq. Current Liabilities Change	0 %	0 %	0 %	-	-
Seq. Cash & cash equivalent Change	0 %	0 %	0 %	-66.46 %	-62.34 %

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 378
Healthcare Sector	# 717
Overall Market	# 2521

Quick Ratio Statistics
High	Average	Low
2.36	1.44	0.52
(Dec 31 2023)		(Dec 31 2025)

Financial Statements
Apollomics Inc 's Current Liabilities	$ 6 Millions	Visit APLM's Balance sheet
Apollomics Inc 's Cash & cash equivalent	$ 3 Millions	Visit APLM's Balance sheet
Source of APLM's Sales		Visit APLM's Sales by Geography

Cumulative Apollomics Inc 's Quick Ratio

APLM's Quick Ratio for the trailling 12 Months

APLM Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-6.67 %	-53.33 %	-76.67 %	-51.11 %	0 %
Y / Y Cash & cash equivalent TTM Growth	-86.87 %	-83.01 %	-65.22 %	-41.82 %	-27.05 %
Quick Ratio TTM	0.52	1.03	3.34	3.57	3.68
Total Ranking TTM	# 2998	#	#	#	#
Seq. Current Liabilities TTM Growth	33.33 %	50 %	-36.36 %	-26.67 %	-33.33 %
Seq. Cash & cash equivalent TTM Growth	-33.12 %	-53.62 %	-40.52 %	-28.84 %	-13.46 %

Quick ratio ranking by company, industry and sector >> Back to APLM Financial Strength Comparisons >> Go to Compare APLM Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2025 to $6.33 millions, cumulative Quick Ratio decreased to 0.52 below the Apollomics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 380 other companies have achieved higher Quick Ratio than Apollomics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 2998.

Explain Quick Ratio?
How much Cash & cash equivalents APLM�s has?
What are APLM�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 381
Healthcare Sector	# 788
Within the Market	# 2998

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.36	2.36	2.36
(Dec 31 2023)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Legend Biotech Corporation	1.42	$ 901.900 Millions	$ 636.400 Millions
Ibio inc	1.41	$ 8.608 Millions	$ 6.106 Millions
Indaptus Therapeutics Inc	1.38	$ 8.508 Millions	$ 6.159 Millions
Macrogenics Inc	1.38	$ 57.217 Millions	$ 41.586 Millions
Arcutis Biotherapeutics Inc	1.37	$ 178.075 Millions	$ 129.838 Millions
Addex Therapeutics Ltd	1.37	$ 1.639 Millions	$ 1.199 Millions
Inflarx N V	1.34	$ 19.545 Millions	$ 14.540 Millions
Inovio Pharmaceuticals Inc	1.34	$ 58.512 Millions	$ 43.669 Millions
Inventiva S a	1.31	$ 113.784 Millions	$ 86.663 Millions
Theriva Biologics inc	1.30	$ 13.056 Millions	$ 10.014 Millions
Moleculin Biotech Inc	1.30	$ 8.878 Millions	$ 6.854 Millions
Uniqure N v	1.28	$ 80.240 Millions	$ 62.919 Millions
Apimeds Pharmaceuticals US, Inc.	1.26	$ 13.273 Millions	$ 10.545 Millions
Vireo Growth Inc.	1.25	$ 103.230 Millions	$ 82.545 Millions
Vanda Pharmaceuticals Inc	1.24	$ 84.851 Millions	$ 68.297 Millions
Amicus Therapeutics inc	1.23	$ 293.536 Millions	$ 237.828 Millions
Nkarta Inc	1.23	$ 39.634 Millions	$ 32.122 Millions
Immunoprecise Antibodies Ltd	1.21	$ 7.919 Millions	$ 6.527 Millions
Puma Biotechnology Inc	1.20	$ 97.528 Millions	$ 81.253 Millions
Greenwich Lifesciences Inc	1.20	$ 6.178 Millions	$ 5.151 Millions
Nature s Sunshine Products inc	1.20	$ 93.891 Millions	$ 78.538 Millions
Nanoviricides inc	1.19	$ 1.559 Millions	$ 1.307 Millions
Keenova Therapeutics Plc	1.16	$ 812.800 Millions	$ 698.700 Millions
Longeveron Inc	1.14	$ 4.661 Millions	$ 4.087 Millions
Akebia Therapeutics Inc	1.13	$ 184.844 Millions	$ 162.938 Millions
Rockwell Medical inc	1.13	$ 10.848 Millions	$ 9.580 Millions
Nervgen Pharma Corp	1.12	$ 16.905 Millions	$ 15.115 Millions
Alkermes Plc	1.08	$ 588.215 Millions	$ 543.437 Millions
Kamada Ltd	1.07	$ 75.469 Millions	$ 70.636 Millions
Cingulate Inc	1.06	$ 10.953 Millions	$ 10.313 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.